Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.

ABSTRACT:

Background

In the pediatric cancer neuroblastoma (NB), patients are stratified into low, intermediate or high-risk subsets based in part on MYCN amplification status. While MYCN amplification in general predicts unfavorable outcome, no clinical or genomic factors have been identified that predict outcome within these cohorts of high-risk patients. In particular, it is currently not possible at diagnosis to determine which high-risk neuroblastoma patients will ultimately fail upfront therapy.

Experimental design

We analyzed the prognostic potential of most published gene expression signatures for NB and developed a new prognostic signature to predict outcome for patients with MYCN amplification. Network and pathway analyses identified candidate therapeutic targets for this MY

SUBMITTER: Hallett RM 

PROVIDER: S-EPMC5423212 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature